EVERSANA’s Jeffrey LaVaute discusses how patient centricity is a foundational principle that informs the healthcare decisions that we make.
Companies continue to announce advancements in artificial intelligence programming as they harness the power of AI and machine learning to aid in drug discovery and development.
This is the Age of Big Data – and also the Age of Data Vulnerability. How we as a society square these two realities will be important to all of us as citizens, consumers, and health communications professionals.
Linguamatics, an IQVIA company, will present the webinar “Applications of Natural Language Processing to Transform Real World Data.”
U.S. Food and Drug Administration Acting Commissioner Ned Sharpless said he plans to “maintain FDA’s current course of action in every area and proceed full-speed ahead,” according to a statement issued by the regulatory agency.
Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.
Nearly two-thirds of U.S. senior business decision-makers rank big data/analytics first among the technologies necessary for enhancing the customer experience. A similar number put “improving data analysis capabilities” at the top of their priorities.
Innoplexus CEO Gunjan Bhardwaj responded to questions from Med Ad News about his company’s study of consumer perceptions of the pharma industry.
If “some” data helps life sciences firms develop insights to improve their businesses, having access to Big Data from multiple sources should lead to many more and much better insights. But more often than not, access to more data is having the opposite effect.
Redefines data-driven marketing services for the life sciences industry; partnership with Medikly further expands the network’s insight-driven client offerings